Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the manufacture of Clexane®

is a leading pharmaceutical company in Egypt and the Middle East and the premier biopharmaceutical company in Africa with over 20 years of experience in cellular and bioprocess engineering. Headquartered in Cairo, Minapharm commercializes over 100 life-saving and life-enhancing products ranging from small molecules to complex genetically-engineered proteins, with an impressive immunotherapy pipeline. Together with its wholly owned Berlin-based subsidiary, ProBioGen AG, Minapharm has established an integrated business model making it to-date the only gene-to-market biopharmaceutical company in the region. Minapharm employs a collective workforce of over 2000 and is listed on the Cairo and Alexandria stock exchange (Symbol: MIPH).

Photo - https://mma.prnewswire.com/media/2297176/Sanofi_Minapharm.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/sanofi-and-minapharm-sign-an-exclusive-agreement-for-localizing-the-manufacture-of-clexane-302010756.html

en | boerse | 67933695 |